Skip to content

Effects of Helicumin on infection index for Helicobacter pylori patients

Effects of Helicumin on infection index for Helicobacter pylori patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0009707
Enrollment
25
Registered
2024-08-16
Start date
2023-07-20
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : * Among natural substances known to have anti-Helicobacter activity, curcumin and mastic gum are reported to have significantly enhanced antibacterial activity when enclosed in ph

Sponsors

Gachon University Gil Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients aged 20 years or older who are on outpatient follow-up in Gachon University Gil Medical Center

Exclusion criteria

Exclusion criteria: Subjects with any of the following will not be included in the study: 1) Received anticancer therapy within 6 months. 2) Chronic hepatitis or cirrhosis of the liver 3) Uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg) or clinically significant (i.e., active) cardiovascular disease: e.g., cerebrovascular accident (within 6 months), myocardial infarction (within 6 months), unstable angina, New York Heart Association Grade II or greater congestive heart failure, or significant cardiac arrhythmia that is not controlled by medication or that could potentially interfere with treatment. 4) History or evidence of congenital bleeding diathesis or coagulopathy with bleeding risk. 5) Any thrombus, embolus within 6 months 6) Major or unhealed wounds, or incompletely healed fractures. 7) Active gastrointestinal bleeding, peptic ulcer. 8) History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months. 9) Pregnant or lactating women. 10) Known hypersensitivity to urea. 11) Diagnosed with phenylketonuria. 12) Have asthma, pneumonia, chronic obstructive pulmonary disease, or other pulmonary disease. 13) Has undergone gastric subtotal resection, gastric anterior resection 14) History of taking PPIs, antibiotics within 2 weeks prior to dosing

Design outcomes

Primary

MeasureTime frame
Change in delta value measured in the urea breath test (before and after taking helicurmin)

Secondary

MeasureTime frame
Evaluate digestive system-related symptoms and changes

Countries

Korea, Republic of

Contacts

Public ContactJi-Hyeon Park

Gachon University Gil Medical Center

pjhaaa@daum.net+82-32-460-3420

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026